Should I buy, hold, or sell BHST stock right now?

BioHarvest Sciences Inc. (BHST) currently earns a Roarable Rating of E (Strong Sell — SELL) with 34/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is BHST's 12-month price target and RQD AI Jury consensus?

BHST's 12-month base price target is $1.48 (range $1.15 to $9.74), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Industrials / BHST

RML (47) STKE (44) CHWM (48) SGLD (45) ⌘ Pro Terminal →

BioHarvest Sciences Inc. (BHST) — RQD Stock Rating Cockpit

$1.66 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.66

BioHarvest Sciences Inc. (BHST) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $37.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BHST Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BHST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, BioHarvest Sciences Inc. (NASDAQ: BHST) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.66 (0.00% 1D, market cap $37.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 486 tracked Industrials issuers, BHST ranks #379 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BHST compare to RML and STKE in the Industrials sector?

▼

Within the Industrials sector (Diversified Equities), BHST carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 59.3%, and ROIC of -35.0%. By comparison, RML (Resolution Minerals Ltd) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $43.0M) and STKE (Sol Strategies Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC —, cap $48.6M). Among the 5-stock peer group, BHST leads on earnings multiple (N/A) while BHST leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BHST?

▼

Per BHST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001723464), BioHarvest Sciences Inc. generated $34.5M in revenue (+37.0% YoY), -$11.1M in net income, and -$9.6M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.66 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BHST)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY BHST SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (18% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 59.3% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.82-7.7% Next Q

Q2 (-2Q)

Grade E$1.68+1.2% Next Q

Q3 (-1Q)

Grade E$1.70-2.4% Next Q

Current

Grade E$1.66-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BHST Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BHST currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Industrials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.69) and Max Pain ($1.74) forces dealer call-delta covering toward $9.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BHST• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BHST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

4830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $1$1.66H: $9

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on BHST

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 59.3% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (28)

11/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like BHST

✓Established market leader in Industrials with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BHST)

✓Walkthrough of BHST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BHST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.90%⚡ TESTING RESISTANCE

2026-11-03O $1.66H $1.66L $1.66C $1.66VOL 2.5K

RES: $1.77SUP: $1.21SMA50: $1.69SMA200: $3.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BHST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BHST Butterfly Map → + Track BHST →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +37.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BHST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BHST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BHST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BHST)

Industrials Rank #379 of 486 ⚔️ RML vs BHST Full Matrix →

1. Head-to-Head Industrials Peer Comparison (BHST vs. RML, STKE, CHWM, SGLD)

Industry: Diversified Equities (43 Tracked Issuers)

Across 486 tracked Industrials securities in the Roarable RQD universe, BioHarvest Sciences Inc. (BHST) ranks #379 by composite RQD confidence (34/100, grade E) and #416 by equity capitalization ($37.6M). Within this direct 5-issuer industry benchmark cohort, BHST leads on earnings valuation at N/A trailing P/E, while BHST leads on capital efficiency and profitability with -35.0% ROIC and 59.3% gross margin. CHWM currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with BHST at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BHST ACTIVE BioHarvest Sciences Inc.	E	34/100	—	59.3%	-35.0%	0.00%	$37.6M	Benchmark Subject
RML Resolution Minerals Ltd	D	47/100	—	—	—	-2.54%	$43.0M	/rml-vs-bhst →
STKE Sol Strategies Inc.	D	44/100	—	—	—	-3.91%	$48.6M	/stke-vs-bhst →
CHWM Chilwa Minerals Limited American Depository Shares	D	48/100	—	—	—	-13.34%	$51.6M	/chwm-vs-bhst →
SGLD Scorpio Gold Corporation	D	45/100	—	—	—	-7.20%	$55.7M	/sgld-vs-bhst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001723464 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioHarvest Sciences Inc. (BHST) reported GAAP revenue of $34.5M (+37.0% vs. FY2024 revenue of $25.2M , and +172.3% cumulative change since FY2023) , GAAP net income of -$11.1M, operating cash flow of -$7.2M, and free cash flow of -$9.6M (-0.7% YoY). On the balance sheet, BHST closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$34.5M	-$11.1M	-$7.2M	-$9.6M	—	—
FY2024 (FY)	2024-12-31	$25.2M	-$12.9M	-$6.7M	-$9.5M	—	—
FY2023 (FY)	2023-12-31	$12.7M	-$12.6M	-$8.5M	-$8.5M	—	—

3. BHST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BHST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BHST compare to RML and STKE in the Industrials sector?

What are the biggest fundamental strengths and SEC risk factors for BHST?

Where is BHST trading relative to its 50-day, 200-day, and 52-week technical levels?

BHST last traded at $1.66 (0.00% on volume of 2,541 shares), positioning the stock -1.78% below its 50-day simple moving average ($1.69) and -48.29% below its 200-day simple moving average ($3.21). Across its 52-week range of $1.37 to $9.28, BHST sits at the 3.7% percentile with a 14-day RSI of 48.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.45 to $1.87).

Direct Sub-Reports: BHST RQD Cockpit BHST 12M Forecast BHST Earnings & Move BHST Dividends & DRIP BHST Insiders & 13F BHST Whale Options BHST Profit Sankey BHST News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

BHST — BioHarvest Sciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BioHarvest Sciences Inc. (BHST) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.66 (0.00% 1D, market capitalization $37.6M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 59.3%, operating margin of -16.2%, and free cash flow yield of —.
Whale 13F & Options Flow (6/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Industrials sector, Diversified Equities industry. Per the recent news wire, the company is developing a proprietary olive cell asset and a sweetener program with Tate & Lyle, with headlines referencing commercial readiness and CDMO licensing opportunities. Per the market data, gross margin is 59.3%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BioHarvest Sciences Inc. (BHST) reported $34.5M in annual revenue (up from $25.2M in FY2024, +37.0% YoY) and -$11.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.7M revenue, -$12.6M net income) through FY2025, BHST scaled operating cash flow to -$7.2M and free cash flow to -$9.6M, backed by $0 in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Industrials with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $1.37 – $9.28 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -16.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph lists no upstream or downstream links and no proprietary signals, so upstream/downstream dependencies, sector correlations, and 2nd-order bottlenecks cannot be mapped from the sources provided.

Key Question #1: Can BHST sustain or expand its -16.2% operating margin and -35.0% ROIC against Diversified Equities peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $34.5M and free cash flow of -$9.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is BHST's equity valuation to Industrials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BHST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioHarvest Sciences Inc. (BHST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BHST Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026

Yahoo Finance report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

BioHarvest Sciences (BHST) Institutional Ownership 2026

MarketBeat report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

BioHarvest says its platform can produce target sweetener in Tate & Lyle program

Yahoo Finance report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme

Yahoo Finance report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

BHST Q1 2025 Earnings: Loss Per Share Slightly Wider Than Expected, Shares Still Move Higher - Earnings Yield Analysis

https://www.dars.gov.et/ report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity

Yahoo Finance report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Beyond Oil Ltd. (BOIL.TO) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Cizzle Brands Corporation (CZZL.NE) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering BioHarvest Sciences Inc. (BHST) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BHST Bull vs. Bear Conversation Board — What's Your Call at $1.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BHST 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $2.16 (+30.1%)

📌 Pinned Debate

Revenue grew from $12.7M in FY 2023 to $34.5M in FY 2025 while reported cash rose to $23.0M, supported by a forensic balance sheet scor

Here is why I am bullish on BHST here at $1.66: Revenue grew from $12.7M in FY 2023 to $34.5M in FY 2025 while reported cash rose to $23.0M, supported by a forensic balance sheet score of 11 of 20.. Compare BHST's -16.2% operating margin and -35.0% ROIC against the rest of Diversified Equities. As long as cash conversion holds up, dips toward $1.58 are getting bought.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Diversified Equities. If gross margin (59.3%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $1.36 (-18.1%)

Spot @ $1.66

ROIC of -35%, FCF yield of 0%, and an insider conviction score of 5 of 20 leave the stock without earnings, cash flow, or insider backi

ROIC of -35%, FCF yield of 0%, and an insider conviction score of 5 of 20 leave the stock without earnings, cash flow, or insider backing.. Look at the math on BHST: paying current EV/EBITDA multiples for -35.0% ROIC and -16.2% operating margins leaves zero margin of safety if Diversified Equities demand softens. I'd wait for a retest of $1.46 before getting long.